Unicycive Therapeutics, Inc. (UNCY) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Unicycive Therapeutics, Inc. (UNCY) Earnings Overview
As of June 21, 2026, Unicycive Therapeutics, Inc. (UNCY) reported trailing twelve-month net income of -$40M, reflecting +70.2% year-over-year growth. The company earned $-0.17 per diluted share over the past four quarters.
Looking at the long-term picture, UNCY's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2018.
Unicycive Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARWR (-$301M net income, -0.2% margin), CYCN (-$5M net income, -170.1% margin), RMTI (-$1.61B net income, -7.7% margin), UNCY has comparable earnings metrics. Compare UNCY vs ARWR →
UNCY Earnings vs Peers
Earnings metrics vs comparable public companies
UNCY Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$27M | +27.7% | -$30M | $-1.67 | - | - |
| 2024 | -$37M | -20.2% | -$32M | $-5.60 | - | - |
| 2023 | -$31M | -69.1% | -$21M | $-1.28 | -4525.0% | -3077.6% |
| 2022 | -$18M | -80.3% | -$18M | $-1.20 | -1898.8% | -1898.2% |
| 2021 | -$10M | -299.4% | -$9M | $-8.60 | - | - |
| 2020 | -$3M | -8.9% | -$2M | $-0.16 | - | - |
| 2019 | -$2M | -105.7% | -$2M | $-0.27 | - | - |
| 2018 | -$1M | - | $-952,000 | $-0.14 | - | - |
Download Data
Export UNCY earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
UNCY — Frequently Asked Questions
Quick answers to the most common questions about buying UNCY stock.
What is UNCY earnings per share (EPS)?
UNCY trailing twelve-month (TTM) diluted EPS is $-0.17, reflecting +70.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Unicycive Therapeutics, Inc.'s net income?
Unicycive Therapeutics, Inc. (UNCY) trailing twelve-month net income is $-40M as of 2025. Earnings grew +70.2% year-over-year.
Is UNCY profitable?
UNCY is not currently profitable on a TTM basis, reporting a net loss of $-40M. Net margin is N/A. Investors should monitor for a return to profitability.
What is UNCY's earnings growth rate?
UNCY compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are UNCY's profit margins?
Unicycive Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -141.1%.
Is UNCY growing earnings?
Yes, UNCY earnings are accelerating — EPS growth of +70.2% exceeds the 5-year CAGR of N/A. TTM net income reached $-40M. Earnings momentum is strengthening.
What was UNCY's best earnings year?
Unicycive Therapeutics, Inc.'s highest annual net income on record is $-1M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were UNCY's earnings last quarter?
UNCY's most recent reported quarter was Q1 2026. Net income was $-13M with diluted EPS of $-0.54. For a full breakdown of all quarters, see the quarterly earnings table on this page.